AbbVie Inc. (ABBV)

106.70 +1.05 (+0.99%) At close: 4:02PM EST

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
http://www.abbvie.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 47,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard A. Gonzalez	Chairman & CEO	7.11M	N/A	1954
Dr. Michael E. Severino	Vice Chairman & Pres	3.98M	N/A	1966
Mr. Robert A. Michael	Exec. VP & CFO	2.76M	N/A	1970
Ms. Laura J. Schumacher	Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.	4.3M	N/A	1963
Dr. Azita Saleki-Gerhardt	Exec. VP of Operations	N/A	N/A	1963
Dr. Thomas J. Hudson	Sr. VP of R&D and Chief Scientific Officer	N/A	N/A	1962
Ms. Elizabeth Shea	VP of Investor Relations	N/A	N/A	N/A
Mr. Timothy J. Richmond	Exec. VP & Chief HR Officer	N/A	N/A	1966
Mr. Scott C. Brun M.D.	VP of Scientific Affairs & Head of AbbVie Ventures	N/A	N/A	N/A
Mr. Henry O. Gosebruch	Exec. VP & Chief Strategy Officer	N/A	N/A	1973

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Corporate governance

AbbVie Inc.’s ISS governance QualityScore as of 3 December 2020 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.